ltrasound contrast developer Acusphere has released data from its phase 3 RAMP-1 (real-time assessment of myocardial perfusion) and RAMP-2 clinical trials for the company's Imagify ultrasound contrast agent.
The Watertown, MA, company said the results from international multicenter trials indicate that Imagify perfusion stress echo is an effective and well-tolerated, minimally invasive approach to evaluating patients with chest pain who are at risk for heart attack.
The echocardiography imaging agent is designed to assess blood flow in heart perfusion and may have potential benefits over nuclear stress testing, including quicker results, lower cost, and no exposure to radioactivity.
Phase 3 data was presented at this week's American Heart Association (AHA) conference in Orlando, FL.
By AuntMinnie.com staff writers
November 6, 2007
Related Reading
Acusphere names new CFO, October 4, 2007
Acusphere in 'partnership' discussions, September 20, 2007
Acusphere to raise $20 million, June 13, 2007
Acusphere reports results from Imagify phase III trials, May 4, 2007
Acusphere taps Bucceri for regulatory post, February 5, 2007
Copyright © 2007 AuntMinnie.com
